Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL20636886 | 0.99 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL6091947 | 0.92 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL6093621 | 0.92 | PTGS2 (0.64) | PTGS2PTGS1 | |
| Fluoride SCHEMBL20636896 | 0.91 | PTGS2 (0.69) | PTGS2PTGS1 | |
| Fluoride SCHEMBL20636890 | 0.91 | PTGS2 (0.62) | PTGS2PTGS1 | |
| Fluoride SCHEMBL20636888 | 0.90 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL31539107 | 0.87 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL31539067 | 0.87 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL31539028 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL5648609 | 0.82 | PTGS2 (0.74) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1463500-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| EP-1406696-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | claimed |
| WO-2004014367-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PHARMACIA CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| WO-2004004833-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | PHARMACIA CORPORATION (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2003059347-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| EP-3509604-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | Trustees of Tufts College (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018187698-A2 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018049008-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049027-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049015-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PD-1 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2003059347-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |